DUO 4 ALLbroad
DUO 4 ALL · Horizon Europe grant · 2025-08-01–2027-01-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2025-ACCELERATOR-02 · scheme HORIZON-EIC-ACC · topic HORIZON-EIC-2025-ACCELERATOR-02-OPEN-01. CORDIS record →
Objective
CroíValve is developing DUO 4 All, a Best-In-Class minimally invasive solution for severe Tricuspid Regurgitation (TR). It is a clear unmet clinical need, with significant impact on mortality, cardiovascular events and quality of life of the large population suffering with this disease. With the highest prevalence of all heart valve diseases, TR is a significant clinical and commercial opportunity. It poses unique challenges in comparison with other heart valve diseases and so needs a solution specifically designed to overcome these challenges. The CroíValve DUO 4 All Tricuspid Coaptation Valve System is a novel approach that provides the right solution for the right heart. The approach puts both the patient and physician at the centre of the design by ensuring it is safe, effective, can accommodate the range of patient anatomies and is quick to learn and implant.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| CROIVALVE LIMITED | IE | coordinator | €2,493,375 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.